Johann E. Gudjonsson, MD, PhD: Mitigating Low-grade Inflammatory Activity in Generalized Pustular Psoriasis

Dr. Gudjonsson discusses a recently published research letter in which he and his colleagues discuss ongoing subclinical inflammation present in between flares in patients with GPP, and the effect of treatment with spesolimab on this inflammation.

Reference:

  1. Lebwohl M, Sarkar M, Krueger J, et al. Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flares. J Clin Invest. 2025; 135(13):e195673.

MORE EXPERT PERSPECTIVES IN GENERALIZED PUSTULAR PSORIASIS

Dr. Bhutani, JCAD’s Special Section Editor in Psoriasis and a member of the National Psoriasis Foundation, discusses the importance of raising GPP awareness and the

Dr. Bhutani discusses the increased level of IL-36 cytokines in patients with generalized pustular psoriasis, playing a key role in the pathogenesis of this disease

Dr. Bhutani discusses how the inconvenience of frequent hospitalizations caused by GPP flare ups can diminish a patient’s quality of life.

Dr. Bhutani describes the unpredictable nature of generalized pustular psoriasis and the downstream comorbidities that can occur if a patient remains untreated.